Global Blood Therapeutics, Inc.
DelistedCIK 1629137fmd_07J4Z43RZYAVFBQPSYD5PBQ27BManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2013 to Jun 30, 2022, 35 periods
| Line item | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 |
|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | – | – | – | 2 | 124 | 195 |
| Cost of revenue | – | – | – | – | – | – | 0 | 2 | 3 |
| Gross profit | – | – | – | – | – | – | 2 | 122 | 191 |
| Research and development | 13 | 16 | 37 | 62 | 88 | 131 | 175 | 155 | 212 |
| Selling, general and administrative | – | – | – | – | 31 | 51 | 117 | 211 | 267 |
| Non-interest income | – | – | – | – | – | 9 | 16 | 6 | 1 |
| Total operating expenses | 16 | 21 | 46 | 83 | 119 | 183 | – | – | – |
| Operating income | (16) | (21) | (46) | (83) | (119) | (183) | (281) | (243) | (288) |
| Non-interest expense | – | – | – | – | – | 0 | 1 | 10 | 15 |
| Interest expense | – | – | – | – | – | – | 31 | 49 | 104 |
| Interest and investment income | 0 | 0 | 0 | – | – | – | – | – | – |
| Other non-operating income (expense) | – | – | – | – | – | 9 | 15 | (4) | (15) |
| Income before taxes | – | (21) | (46) | (82) | (117) | (174) | (267) | (248) | (303) |
| Income tax expense | – | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | – | (21) | (46) | (82) | (117) | (174) | (267) | (248) | (303) |
| Net income | (18) | (21) | (46) | (82) | (117) | (174) | (267) | (248) | (303) |
| Net income to common shareholders | (20) | (24) | (51) | (82) | – | – | – | – | – |